Tiziana Life Sciences PLC - London-based biotechnology firm - Says the United States Patent & Trademark Office has granted a patent for its proprietary fully human monoclonal antibody Foralumab for the treatment of Crohn's disease. The patent will be published by the USPTO on September 1 as Patent No. 10,759,858.
"We are very excited about the continued development of the oral administration of Foralamab for the treatment of Crohn's disease because this alternative route of administration seems to minimize toxicity and we believe it would maximize clinical activity by acting topically in the gut to inhibit inflammation," said Tiziana's Chief Executive & Chief Scientific Officer Kunwar Shailubhai.
Current stock price: 167.50 pence
Year-to-date change: up over four-fold.
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
